Zenas BioPharma, Inc. (ZBIO) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.28
↓-16% vs avg
5yr avg: 3.90
30Y Low1.1·High6.7
ROE
↑
-136.2%
↓+45% vs avg
5yr avg: -249.1%
30Y Low-362%·High-136%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ZBIO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Zenas BioPharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $793M | $1.6B | $342M | — | — |
| Enterprise Value | $762M | $1.6B | $23M | — | — |
| P/E Ratio → | -2.10 | — | — | — | — |
| P/S Ratio | 79.29 | 162.41 | 68.44 | — | — |
| P/B Ratio | 3.28 | 6.71 | 1.10 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ZBIO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | 159.35 | 4.70 | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
ZBIO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Zenas BioPharma, Inc. earns an operating margin of -2113.8%. Operating margins have compressed from -74.3% to -2113.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -136.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -2682.8% | 100.0% | — |
| Operating Margin | -2113.8% | -2113.8% | -3277.8% | -74.3% | — |
| Net Profit Margin | -3777.4% | -3777.4% | -3139.8% | -74.2% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -136.2% | -136.2% | -362.0% | — | — |
| ROA | -100.2% | -100.2% | -71.7% | -52.0% | -159.9% |
| ROIC | -154.5% | -154.5% | — | — | — |
| ROCE | -66.7% | -66.7% | -91.7% | -79.4% | -156.7% |
ZBIO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $111M exceeds total debt of $80M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.33 | 0.33 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.13 | -1.02 | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -50.56 | -50.56 | — | — | — |
Net cash position: cash ($111M) exceeds total debt ($80M)
ZBIO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Zenas BioPharma, Inc.'s current ratio of 5.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.57x to 5.61x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 5.61 | 5.61 | 6.21 | 2.57 | 2.64 |
| Quick Ratio | 5.61 | 5.61 | 6.21 | 2.57 | 2.64 |
| Cash Ratio | 5.48 | 5.48 | 6.12 | 2.44 | 2.59 |
| Asset Turnover | — | 0.03 | 0.01 | 0.73 | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
ZBIO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Zenas BioPharma, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $45M | $42M | $38M | $38M |
Peer Comparison
Compare ZBIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ZBIOYou | $793M | -2.1 | — | — | 100.0% | -2113.8% | -136.2% | -154.5% | — |
 ARCT | $198M | -2.9 | — | — | 95.5% | -111.5% | -28.9% | -277.1% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARDX | $1B | -22.3 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RCUS | $2B | -7.1 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ALKS | $7B | 31.4 | 22.9 | 15.6 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 HALO | $8B | 27.6 | 11.5 | 13.0 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 ACAD | $4B | 9.3 | 25.5 | 34.8 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.8 | 6.7 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
What if you invested $1,000 in ZBIO 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ZBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ZBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationZBIO vs ARCT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Arcturus Therapeutics Holdings Inc..
Compare NowZBIO — Frequently Asked Questions
Quick answers to the most common questions about buying ZBIO stock.
What is Zenas BioPharma, Inc.'s P/E ratio?
Zenas BioPharma, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
What is Zenas BioPharma, Inc.'s ROE?
Zenas BioPharma, Inc.'s return on equity (ROE) is -136.2%. The historical average is -249.1%.
Is ZBIO stock overvalued?
Based on historical data, Zenas BioPharma, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Zenas BioPharma, Inc.'s profit margins?
Zenas BioPharma, Inc. has 100.0% gross margin and -2113.8% operating margin.